While at least 10 states demand that pharmacy benefit managers disclose information about their financial negotiations with drug manufacturers, observers say the strategy may backfire. States believe the transparency will give them greater leverage that will lead to lower prices, but it's the pharmaceutical companies that may win if the negotiating power of PBMs is destroyed.

Related Summaries